Researchers from the University of Pennsylvania have developed a gene therapy that successfully treats a form of macular degeneration in a canine model. The work sets the stage for translating the findings into a human therapy for an inherited disease that results in a progressive loss of central vision and which is currently untreatable.
The study, published this week in Proceedings of the National Academy of Sciences, was led by Karina E. Guziewicz, a research assistant professor in Penn’s School of Veterinary Medicine, and Artur V. Cideciyan, a research professor of ophthalmology in Penn’s Perelman School of Medicine. The research is part of a long-standing partnership between Penn Vet and Penn Medicine scientists to push forward gene and other novel therapies for blinding disorders.
“In the eye, you have these two integral retinal cell layers that puzzle into one another and, like a zipper, they interweave your vision cells and the support cells,” Cideciyan says. “What this disease is doing is basically unzipping those layers, and what we’ve done is rezip them, bringing them together tightly.”
“With this research,” Guziewicz says, “we have demonstrated that there is a therapy that is working in a large animal model. Following safety studies, a human clinical trial could be less than two years away.”
Guziewicz and Cideciyan’s colleagues who collaborated on the work included vision scientists from Penn Vet’s Division of Experimental Retinal Therapies, Gustavo D. Aguirre, professor of medical genetics and ophthalmology, and William Beltran, professor of ophthalmology; and from Penn Medicine Samuel G. Jacobson, professor of ophthalmology.
Best disease, or vitelliform macular degeneration, is an inherited blinding disorder caused by mutations in the BEST1 gene. It often manifests in children and young adults, gradually robbing them of their central vision.
Through a variety of studies during the last several years, the Penn team has shown that dogs, too, develop a strikingly similar disease. A 2014 study led by Beltran revealed that dogs, like humans, have a tiny region at the center of their retina that is densely packed with cone photoreceptor cells—those responsible for reading, driving, and perceiving fine details—called a fovea. BEST1 mutations in both humans and dogs compromise the fovea, leading to vision loss.
Based on success treating other blinding diseases, the group has been developing a gene therapy to treat this condition. And working with the canine model, Guziewicz and colleagues reported last year the discovery of the underlying defect responsible for disease, the failure of a supporting structure known as the retinal pigment epithelium, or RPE, to tightly connect to the light-sensing photoreceptor cells. That finding gave the researchers the outcome measures they needed to determine with confidence whether a gene therapy would work.
In the newly published study, the researchers further probed the canine Best disease while also examining human patients with BEST1 mutations to see if analogous defects could be seen.
While Best disease and related conditions were known to affect central vision, it had long been known that the disorders involved dysfunctions all across the retina. Examining the retinas of dogs with disease mutations, the researchers found a retina-wide abnormality; the internal surface of the RPE, critical for communication with the light-sensing photoreceptor cells, failed to develop normally, preventing the photoreceptors from coming into close contact. This could be detected very early, when the affected dogs were only 6 weeks old.
“This was unexpected,” says Aguirre, “and helps explain this puzzling finding in the disease that, while patients have lesions that are very local, when you do electrophysiological measurements you see that there is a retina-wide defect. Now that we can see this separation happening very early between the RPE and photoreceptors, we know that the disease involves a structural abnormality across the retina that precedes the loss of photoreceptor cells.”
An additional finding that arose when the dogs were examined under light was that light exposure dramatically increased the severity of the RPE-photoreceptor separation. When dogs were returned to darkness, the separation decreased.
It’s unknown whether this association with light is present in human patients. But the researchers did take steps to show that a similar separation between RPE and photoreceptors is affecting vision. By measuring the time it took for patients to adjust to darkness, or acquire “night vision,” the researchers obtained a proxy for the time it takes for nutrients to diffuse between these two layers of cells, a process that enables dark adaptation. They showed that a longer distance was associated with much slower rates of nutrient transport.
“This flow of nutrients normally occurs over a very small distance,” Cideciyan says. “So if you have a separation between these two layers, the recovery rate to get night vision slows down. The implication is that, if we could correct the apposition of these two tissues, we would correct the visual defect as well.”
That is what the researchers set out to do in testing the gene therapy construct. Using a harmless viral vector, they injected a healthy copy of the BEST1 gene, using either the canine or human version of the gene, into the dogs with the canine version of Best disease, at early- and middle-disease stages.
Remarkably, they were able to correct both mild and more severe lesions. Close examination of the eyes of treated dogs revealed that the gene therapy restored the “zipper” structure between RPE and photoreceptor cells. To ensure their therapy was functioning to correct this RPE-photoreceptor interface, they exposed to light the eyes of dogs that had been previously injected with gene therapy and saw that the triggered RPE-photoreceptor cell separation did not occur in the area of the retinas that had been treated.
“Since we understand the mechanism of disease better than before,” says Guziewicz, “it also allows us to understand the mechanism of rescue. We can visualize these projections extending from the RPE that never existed before; it’s incredible. That restored the proper apposition between those two cell layers.”
The therapy appears to be lasting, as the treated dogs’ eyes remained disease-free for as long as five years.
Work remains to be done before embarking on human clinical trials, including identifying which patients might benefit, assessing how far advanced a disease could be and still be effectively treated, and ensuring safety so as not to compromise vision that the patients still have. But, given the closeness with which dogs recapitulate the human disease, the researchers are hopeful that the findings will translate.
“On a human level, there are a lot of families who know that previous generations have had this disease, and the young people can live in fear of whether it is going to affect them,” Jacobson says. “This is the unveiling of a mechanism and a treatment for a previously untreatable form of juvenile or inherited macular degeneration, and that’s a major step forward.”
The Latest on: Macular degeneration
via Google News
The Latest on: Macular degeneration
- Juvenile Macular Degeneration (Stargardt Disease) Pipeline Review, H1 2019 - Therapeutics Review of 15 Companies & 20 Drug Profiles on April 18, 2019 at 1:35 am
Dublin, April 18, 2019 (GLOBE NEWSWIRE) -- The "Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H1 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. ... […]
- Innovent Announces First Patient Dosed in a Phase I Clinical Trial of IBI302 for the Treatment of Wet AMD on April 17, 2019 at 5:08 pm
"Age-related macular degeneration (AMD) is one of the leading causes of irreversible vision impairment among China's elderly population. Although the efficacy of current therapies for wet AMD is ... […]
- Adverum Announces Clinical Hold, But It Should Not Hinder Its Gene Therapy Path on April 17, 2019 at 7:53 am
Adverum announced that the FDA has placed a clinical hold on one of its gene therapy products known as ADVM-022 to treat patients with wet age-related macular degeneration. Responses for the FDA's ... […]
- A hidden footprint: embryological origins of age related macular degeneration on April 17, 2019 at 6:27 am
To address this, Sivapathasuntharam et al.  examined retinal development in Cfh−/− and Cfh+/− mice and showed significant disruptions at the retinal/RPE interface. However, after retinal ... […]
- Ask Amy: Older mother drives but never arrives on April 16, 2019 at 10:09 pm
(My stepfather doesn’t drive, and my mom has macular degeneration, but my brother offered to pick them up.) We had flown across the country to attend this wedding, and I resent that my mother didn’t ... […]
- Treatment for Wet Age-Related Macular Degeneration Receives Biologics License Application Approval on April 16, 2019 at 6:54 am
Officials with the FDA have accepted Novartis’ Biologics License Application (BLA) for brolucizumab (RTH258), a humanized single-chain antibody fragment (scFv), for the treatment of wet age-related ... […]
- Ophthotech in-licenses gene therapies for type of macular degeneration; shares up 29% after hours on April 11, 2019 at 6:19 pm
Thinly traded nano cap Ophthotech (NASDAQ:OPHT) is up 29% after hours in response to its in-licensing deal for adeno-associated virus (AAV) gene therapy candidates for Best vitelliform macular ... […]
- LumiThera Announces First Patient Enrollment in the European Multi-Center, LIGHTSITE II Clinical Study to Treat Dry Age-Related Macular Degeneration on April 11, 2019 at 4:49 am
"I am delighted that we are able to offer some of our patients this very exciting new treatment," remarked Professor Ben Burton, Visiting Professor at the University of East Anglia, and ... […]
- Experimental drug ‘slows down macular degeneration’ on April 11, 2019 at 4:45 am
An experimental drug may be twice as good at fighting vision loss as previously thought, according to new research by Johns Hopkins Medicine. The new research shows that the compound, named AXT107, ... […]
- Juvenile Macular Degeneration (Stargardt Disease) Pipeline Review, H1 2019 Report - ResearchAndMarkets.com on April 5, 2019 at 5:23 am
DUBLIN--(BUSINESS WIRE)--The "Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H1 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. Juvenile Macular ... […]
via Bing News